Table 1.
Characteristics of the ten studies included in the meta-analysis of the prognostic value of insulin-like growth factor 1 receptor in breast cancers
| Reference | No of patients | Patients source | Technique | Cutoff survival | HR estimation | HR (95% CI) of OS/BCSS | HR (95% CI) of DFS |
|---|---|---|---|---|---|---|---|
| Bonneterre et al5 | 297 | France | RIA | ≥1% Mem | Survival curve | OS: 0.29 (0.17–0.49) | 0.29 (0.18–0.47) |
| Railo et al8 | 126 | Finland | RIA | ≥4% Mem | Survival curve | No | 1.86 (0.79–4.38) |
| Ueda et al15 | 150 | Japan | IHC | ≥10% weak or moderate complete Mem staining | Given by author | No | 0.52 (0.23–1.18) |
| Köstler et al16 | 72 | Austria | IHC | At least moderate Mem and/or Cyto staining | Given by author | OS: Mem: 0.76 (0.37–1.54) Cyto: 0.82 (0.42–1.60) |
No |
| Law et al17 | 112 | Canada | IHC | At least moderate Mem staining | Survival curve | OS: 1.47 (0.81–2.67) | No |
| Kim et al9 | 283 | South Korea | IHC | ≥26% (no mention) | Given by author | OS: 0.22 (0.06–0.79) | 0.46 (0.23–0.91) |
| Fu et al18 | 297 | Japan | IHC | ≥10% Mem and/or Cyto staining | Given by author | BCSS: Mem: 0.36 (0.06–2.05) Cyto: 0.49 (0.14–1.74) |
Mem: 0.47 (0.19–1.14) Cyto: 0.48 (0.16–1.14) |
| Hartog et al19 | 368 | The Netherlands | IHC | >10% Mem and/or Cyto staining | Given by author | BCSS: Mem: 1.19 (0.61–2.34) Cyto: 0.38 (0.20–0.74) |
Mem: 1.42 (0.08, 2.49) Cyto: 0.61 (0.34–1.09) |
| Yerushalmi et al20 | 2,871 | Canada | IHC | Strong Mem staining | Survival curve | BCSS: 0.50 (0.40–0.63) | No |
| Shin et al21 | 968 | South Korea | IHC | >10% Mem staining | Survival curve | OS: 0.78 (0.50–1.21) | 1.07 (0.74–1.55) |
Abbreviations: BCSS, breast cancer-specific survival; Cyto, cytoplasmic; CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; IHC, immunohistochemistry; Mem, membranous; OS, overall survival; RIA, radioimmunoassay.